The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
11 February 2019
Accrol Group Holdings plc
(AIM: ACRL)
Director's Dealing
Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter, announces that, Dan Wright, Executive Chairman of Accrol has today purchased 150,000 ordinary shares of £0.001 each ("Ordinary Shares") at a price of 20.5p per Ordinary Share. Following this purchase, he now holds 2,370,308 Ordinary Shares representing 1.21% of the current Issued Share Capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
a) |
Name |
Dan Wright
|
|
2 |
Reason for the notification |
||
a) |
Position/status |
Executive Chairman
|
|
b)
|
Initial notification /Amendment |
Initial notification |
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
a) |
Name |
Accrol Group Holdings plc |
|
b) |
LEI |
213800MC56M5G69RJ226 |
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a)
|
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.001
ISIN: GB00BZ6VT592 |
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
c) |
Price(s) and volume(s) |
Price(s) 20.5p
|
Volume(s) 150,000
|
d) |
Aggregated information - Aggregated volume - Price |
|
|
e) |
Date of the transaction |
11 February 2018 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
Enquiries:
For further information, please contact: |
|
||
|
|
||
Accrol Group Holdings plc |
|
||
Dan Wright, Executive Chairman |
+44 (0) 1254 278 844 |
||
Gareth Jenkins, Chief Executive Officer |
+44 (0) 1254 278 844 |
||
|
|
||
Zeus Capital Limited (Nominated Adviser & Broker) |
|
||
Dan Bate / Andrew Jones |
+44 (0) 161 831 1512 |
||
Dominic King / John Goold |
+44 (0) 203 829 5000 |
||
|
|
||
Belvedere Communications Limited |
|
||
Cat Valentine (cvalentine@belvederepr.com) |
+44 (0) 7715 769 078 |
||
|
+44 (0) 7967 816 525 |
||
Llew Angus (langus@belvederepr.com) |
+44 (0) 7407 023 147 |
Notes to Editors
Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK.
Accrol operates from three sites:
· A manufacturing, storage and distribution facility in Blackburn;
· A facial tissue plant, also in Blackburn; and
· A manufacturing, storage and distribution facility in Leyland.